CGRP Education & Research Forum
Already a member? Become a member Register
youtubeLinkedIn
News

A phase 2/3, multicentre, randomised, double-blind, placebo controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of multiple dosing regimens of oral AGN-241689 in episodic migraine prevention

Atogepant (AGN-241689) Study title/design: A phase 2b/3, multicentre, randomised, double-blind, placebo controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of multiple dosing regimens of oral AGN-241689 in episodic migraine prevention Trial NCT02848326: https://clinicaltrials.gov/ct2/show/NCT02848326?term=AGN-241689&rank=1 Aim To evaluate the safety and tolerability of AGN-241689 (atogepant) 10 mg once daily (QD), 30 mg QD, 30 mg twice …

Read more »